Industry News

Stay up to date with the latest news in the industry

LATEST NEWS

Sanofi-Aventis Multiple Sclerosis Drug Shows Reduced Annualised Relapse Rate

Sanofi-aventis has announced that its investigational once-daily oral drug teriflunomide for the treatment of relapsing multiple sclerosis (RMS), has met the primary endpoint in its Phase III trial.

02 September 2010





Newsletter Sign-Up
For all the latest news in the industry, sign up here

Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development